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Signalling dosageIn contrast to the majority of sporadic colorectal cancer which predominantly occur in the distal colon, most
mismatch repair deﬁcient tumours arise at the proximal side. At present, these regional preferences have not
been explained properly. Recently, we have screened colorectal tumours for mutations in Wnt-related genes
focusing speciﬁcally on colorectal location. Combining this analysis with published data, we propose a
mechanism underlying the side-related preferences of colorectal cancers, based on the speciﬁc acquired
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Epidemiological data show that 55–70% of all colorectal cancers
develop in the distal half of the colon, i.e. distal to the splenic ﬂexure
(also referred to as “left-sided colon”) [1]. However, colorectal
tumours harbouring a DNA mismatch repair (MMR) deﬁciency form
an exception as they are predominantly located in the proximal part of
the colon (also referred to as “right-sided colon”) [2–6] (Fig. 1). About
15% of all colorectal tumours are characterised by a defect in the MMRmachinery, which consists of a handful of proteins involved in the
recognition and repair of DNA mismatches that occur during
replication [5,6]. These can be either base substitution mutations
incorporated during DNA synthesis or, occurring more frequently,
slippage of the DNA polymerase at repetitive sequences resulting in
small insertions/deletions of base pairs. In case of a defective MMR
system these mistakes are not repaired correctly, resulting in a
mutator phenotype at the nucleotide level. The MMR genes most
commonly affected in colorectal cancer are MSH2, MLH1, and MSH6.
About 2–3% of all colorectal cancers arise in families carrying
heterozygous germlinemutations in either one of these genes, leading
to the autosomal dominant disease referred to as Lynch syndrome.
MMR deﬁcient tumours may also arise in a sporadic context,
corresponding to 10–12% of all colorectal cancers. In contrast to
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Fig. 1. Distribution of cancers along the colorectal tract. Looking at the distribution of
tumours along the colorectal tract, the majority is identiﬁed in the distal colon.
However, tumours harbouring a mismatch repair (MMR) defect form an exception, as
they are predominantly located in the proximal part of the colon. The colon is divided in
proximal and distal side at the splenic ﬂexure here marked by a diagonal line.
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with low levels of chromosomal instability and loss of heterozygosity
(LOH), are more likely to be diploid, and are preferentially located in
the proximal colon [5,6].
At present it is unknown why different types of colorectal cancer
occur predominantly at one side of the colorectal tract. Both sides ofa
Fig. 2. Schematic representation of the Wnt/β-catenin signalling pathway. (a) In the abse
consisting of APC, Axin, GSK3 and CKI, and marked for degradation by phosphorylation a
mediated degradation in the proteasome. As a result, no free β-catenin enters the nucleus to
(b) When Wnt ligand binds to the frizzled and LRP5/6 receptors, formation of the destructio
target genes such as c-Myc.
Figure adapted from reference [13] with permission from Lab. Invest., courtesy of Dr. Tongthe colon differ in various aspects [7]. For example, whereas the
proximal colon originates from the embryonicmidgut, the distal colon
is formed by the hindgut. Both sides also differ in their bile acid
metabolism, water resorption, luminal content, bacterial colonisation,
short-chain fatty acid production, and various other features. None of
these aspects can however easily explain the side preferences of
colorectal tumours. Here, we present data supporting our hypothesis
that these side preferences may in part be explained by speciﬁc
acquired genetic defects in β-catenin signalling along the colorectal
tract. First, wewill review the literature related to β-catenin signalling
dosage and its importance in tumour formation.
2. Wnt/β-catenin signalling defects in colorectal cancer
Themajority of colorectal tumours, including thosewith amismatch
repair defect, acquire mutations resulting in aberrant activation of the
Wnt/β-catenin signalling pathway [8–10]. This pathway normally
represents one of the main regulatory mechanisms to preserve tissue
homeostasis in the adult organism by regulating the balance between
self-renewal, differentiation and apoptosis in several adult stem cell
niches [9]. As depicted in Fig. 2, in the absence of signalling from an
extracellularWnt ligand,β-catenin is degradedby an intracellularmulti-
protein complex. This so-called destruction complex encompasses two
kinases, GSK3 andCKI-α, theAdenomatous Polyposis Coli (APC) tumour
suppressor, β-catenin (ofﬁcial gene name CTNNB1), and the scaffold
proteins AXIN1 and AXIN2. Formation of this complex catalyses Ser/Thr
phosphorylation of β-catenin at speciﬁc N-terminal residues, thereby
triggering its subsequent ubiquitination and proteolytic degradation. In
the presence of the ligand, Wnt molecules bind to the frizzled and
LRP5/6 receptors and inhibit the formation of the destruction complex.
β-Catenin is now free to accumulate intracellularly and translocate into
the nucleus where it associates with members of the TCF/LEF family of
transcription factors, thus regulating the expression of speciﬁc down-
streamWnt target genes and affecting subsequent cellular decisions.
In a large number of tumour types enhanced β-catenin signalling
strongly contributes to tumour growth, underscoring its importance
in maintaining tissue homeostasis throughout the organism [11,12].b
nce of an extracellular Wnt ligand, β-catenin is recruited into a destruction complex
t its N-terminus. The phosphorylated β-catenin binds to β-Trcp triggering ubiquitin-
form transcriptional complexes with LEF/TCF and activate downstream gene expression.
n complex is inhibited. β-catenin can enter the nucleus and regulate the expression of
-Chuan He, University of Chicago Medical Center, Chicago, USA.
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copies of the APC gene, resulting in inefﬁcient breakdown of intracellular
β-catenin and enhanced nuclear signalling. In a subset of tumours,
oncogenicβ-cateninmutationswithin exon3 are observed atN-terminal
phosphorylation residues, making the protein more resistant to
proteolytic degradation [8,9,11,13]. In both scenarios, the aberrantly
stabilised β-catenin constitutively activates downstreamWnt/β-catenin
target genes, triggering a genetic programme that initiates tumour
formation.
Enhanced β-catenin signalling, however, is not only involved in
tumour initiation but has also been implicated in tumour progression.
Although thepresenceofAPCorCTNNB1mutationspredicts constitutive
β-catenin signalling in each tumour cell, heterogeneous patterns of
nuclear, cytoplasmatic, and membrane-bound β-catenin are observed
within colorectal tumours [14]. Patches of cells with high levels of
nuclear β-catenin are associated with tubular branching, invasion, and
epithelial tomesenchymal transitions [15]. Nuclearβ-catenin staining is
also strongly correlatedwith tumour size and grade of dysplasia, and the
highest levels of nuclear β-catenin are observed at the invasion fronts
of adenocarcinomas [16,17]. Based on these observations, enhanced
β-catenin signalling has been implicated in the induction of an invasive
and metastatic phenotype of colorectal tumours [18,19].
Up to 85% of colorectal cancers with a functional MMR system are
characterised by APC mutations, whereas CTNNB1 mutations in this
subset of tumours are rare [20,21]. In colorectal tumours with a MMR
defect, APC mutations are detected in about 50% of the cases, whereas
the rate of CTNNB1mutations is 10% in sporadicMMRdeﬁcient tumours
and reaches 30% in Lynch syndrome associated colorectal cancers
[10,20,22–26]. In a signiﬁcant proportion of MMR deﬁcient tumours,
mutationshave also been reported in theWnt-relatedAXIN1,AXIN2, and
TCF7L2 (also known as TCF4) genes, although the relevance of these
mutations for tumour growth is unclear as they can coincide with
mutations in either APC or CTNNB1 [10,27–30]. These data show that the0
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Fig. 3. APC truncations and residual β-catenin regulating activity. Compiling various studies [
based on the arbitrary β-catenin signalling level associated with their residual β-catenin reg
the left. Truncated proteins with 2 repeats have to include the CID domain to acquire ad
subdivision shown here is used throughout the paper. Truncated proteins with 1, 2, or 3 repea
protein we have demarcated the mutation cluster regions (MCR) for APC mutations observmajority of colorectal tumours, irrespective of the underlying form of
genetic instability, acquire mutations resulting in aberrant activation of
the Wnt/β-catenin signalling pathway.
3. Level of β-catenin signalling associated with APC and CTNNB1
mutations
The APC gene consists of an open reading frame of over 8500
basepairs encoding a 312 kDa protein (Fig. 3). Several motifs in the
central domain are responsible for regulating intracellular β-catenin
levels. Four 15 aa repeats bindβ-catenin, whereas seven 20 aamotifs are
involved in both binding and downregulation of β-catenin. Interspersed
within those 20 aa repeats are three binding sites for AXIN1/AXIN2
required for anoptimal recruitment of APC into thedestruction complex.
More recently, anadditionalmotif, referred to as theβ-catenin inhibitory
domain (CID), was identiﬁed directly following the second 20 aa repeat,
which appears to contribute to APC's ability to regulate β-catenin
signalling [31].
The vast majority of APC mutations result in truncated proteins that
lack all AXIN1/AXIN2 binding motifs while retaining between one and
three 20 aa repeats associated with the down-regulation of intracellular
β-catenin levels. Originally, all mutations within the APC gene were
considered to fully impair its β-catenin downregulating activity.
However, subsequent studies have shown that most truncated proteins
observed in tumours, have retained residual activity in regulating
β-catenin signalling, which turns out to be of great importance for
successful tumour formation. Truncated proteins with two or three 20
aa repeats inhibit signallingalmost as efﬁciently as full-lengthAPCwhen
overexpressed in vitro [31–35]. Moreover, even when expressed at
endogenous levels, a truncated Apc protein encompassing three 20 aa
repeats shows considerably more β-catenin downregulating activity
than cells only expressing truncated proteins where all β-catenin
regulating domains are lacking [36–38]. Additionally, a truncated APC1513 - 1577
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Fig. 4.Using a β-catenin reporter assay, Rosin-Arbesfeld et al. showed that colorectal cancer cell lines expressing oncogenic variants of β-catenin, induce reporter activity to the same
extent as cell lines expressing truncated APC proteins retaining three 20 aa repeats. For the other cell lines, the inverse correlation between the β-catenin signalling strength and the
number of 20 aa repeats remaining in the truncated APC protein can be seen.
Figure adapted from reference [44] with permission from EMBO J, courtesy of Dr. Mariann Bienz, MRC Laboratory of Molecular Biology, Cambridge, UK.
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the nucleus, andmay therefore reduceβ-catenin signalling activity [39–
41]. Thus, although nearly all of the truncated APC proteins observed in
colorectal tumorigenesis are impaired in their β-catenin downregulat-
ing activity, they donot represent null alleles and code for some residual
β-catenin regulating activity.
Compiling the results of the above-mentioned studies, we have
categorised the mutant APC proteins in groups based on their residual
activity (Fig. 3). An inverse correlation is observedbetween the number of
20 aa repeats and the resulting level of β-catenin signalling, i.e. more
repeats means a lower β-catenin signalling level to the nucleus. As the
second 20 aa repeat by itself cannot bind β-catenin efﬁciently [42],
truncated APC proteins with two repeats require the CID domain directly
following this repeat, in order to retain additional breakdownactivity [31].
Therefore, truncated APC proteins including two 20 aa repeats are at least
1430 residues in length to give them a distinctive increased β-catenin
regulatingactivity comparedwith truncatedproteinswithone repeat. The
codon boundaries shown in Fig. 3 are used throughout the paper.
How do oncogenic CTNNB1 mutations ﬁt within this signalling
spectrum? In most cases only one CTNNB1 allele is affected, meaning
that only half the β-catenin produced is resistant to degradation,
whereas the entireβ-catenin signalling pool is affected in case of a full-
blown APC inactivation. Furthermore, Wang et al. have shown that
phosphorylation of β-catenin at S33/S37/T41 still occurs efﬁciently in
the presence of a mutant S45 residue, suggesting that one of the
prevailing mutant forms of β-catenin in CRC is not fully resistant to
proteolytic degradation [43]. Accordingly, as depicted in Fig. 4,
measuring the signalling activity in various colorectal cell lines
harbouring speciﬁc APC or CTNNB1mutations, showed that oncogenic
CTNNB1 mutations confer a low induction of a β-catenin reporter
construct, similar to cell lines expressing truncated APC proteins
retaining three 20 aa repeats [44]. As such, these observations suggest
that oncogenic CTNNB1mutations result in a modest activation of the
β-catenin signalling pathway.
4. Tissue-speciﬁc selection for β-catenin signalling defects
Tumour formation is considered an evolutionary process where
clonal expansion occurs through spontaneously acquired somaticmutations,which are subsequently selected upon the growth advantage
they provide to the tumour cell. Mutations that do not provide the cell
with sufﬁcient growth advantage will not allow clonal expansion and
tumour formation. On the other hand, mutations which have too much
impact on the cellular phenotype will not be compatible with cell
survival and lead to cell death. In both cases, these mutations will not
contribute to the somatic mutation spectrum that is ﬁnally observed in
tumours. The Wnt/β-catenin signalling pathway represents a prime
example for this concept, as we and others have shown that during
tumour initiation speciﬁc APC genotypes are selected on the basis of the
speciﬁc level of residual β-catenin down-regulating activity of the
resulting truncated proteins, rather thanon the complete inactivation of
this signal transduction regulatory function of APC [45–51]. According
to this “just-right” signalling model, a speciﬁc degree of APC
impairment is required to allow sufﬁcient accumulation of nuclear
β-catenin and activation of the downstream target genes relevant for
tumour formation [48]. However, cells characterised by β-catenin
signalling levels above a given threshold undergo apoptosis and hence
will not contribute to tumour formation. At the molecular level, low
levels of β-catenin signalling mainly modulate the expression of the
most accessible and responsive genes, whereas high doses of nuclear
β-catenin will also affect the expression of less responsive ones [37].
Activation of an apoptotic response requires higher levels of β-catenin
signalling [52–54]. Similar results have been reported for the proto-
oncogene c-Myc, one of the main target genes activated by the
Wnt/β-catenin signalling pathway [55], and required for themajority
of Wnt/β-catenin target gene activation following Apc loss [56]. A
tissue-speciﬁc increase in proliferation was observed in a transgenic
mouse model expressing c-Myc at modest elevated levels, whereas the
expressionof pro-apoptotic geneswas robustly inducedwhenc-Mycwas
expressed at high levels [57]. Thus, eliminating cells with too much
signalling of proto-oncogenes such asβ-catenin or c-Myc, appears to be a
mechanism to safeguard against tumour formation. Thismechanism also
applies to APC-driven tumour formation.
The APC gene is a large gene, subject to a variety of mutations that
could theoretically impair its function. Nevertheless, the mutations
observed in colorectal as well as other tumour types converge to a
small region termed the mutation cluster region (MCR), coinciding
with the region in between the ﬁrst 20 aa repeat and the AXIN binding
223C. Albuquerque et al. / Biochimica et Biophysica Acta 1816 (2011) 219–231domain (Fig. 3) [11]. Different APC genotypes have been observed in
different tumour types throughout the body, suggesting that tissue-
speciﬁc dosages of β-catenin signalling are selected to efﬁciently
trigger tumorigenesis. In about 80% of colorectal tumours with APC
mutations, at least one of the mutated alleles code for truncated APC
proteins retaining one or, less frequently, two 20 aa repeats, resulting
in relatively high to moderate β-catenin signalling levels [31,45,47–
49]. Colorectal tumours solely expressing truncated APC proteins
lacking all 20 aa repeats or expressing longer truncated proteins, are
less frequently observed. According to the “just-right” signalling
hypothesis, this can be explained by assuming that these truncated
APC proteins do not provide the optimal level of β-catenin signalling
to efﬁciently initiate colorectal tumour growth.
Desmoid tumours (also named aggressive ﬁbromatosis) are rare
mesenchymal tumours likely selecting for low to moderate β-catenin
signalling defects. This is either accomplished by acquiring truncated
APC proteins retaining two or three 20 aa repeats (~5–10% of cases),
or more frequently an oncogenic CTNNB1 mutation (~80%) [58–60].
These truncated APC proteins with 2–3 repeats, or oncogenic CTNNB1
mutations, are also the most frequently observed alterations in polyps
arising in the gastric and duodenal epithelium [61–64]. The spectrum
of mutations in the β-catenin signalling pathway observed in these
tumour types, is consistent with our hypothesis that oncogenic
CTNNB1 mutations provide an equivalent induction of β-catenin
signalling as truncated APC proteins retaining 2–3 repeats (Fig. 4).
The selection for speciﬁc dosages of β-catenin signalling is corrobo-
rated by the phenotypes of familial adenomatous polyposis (FAP)
patients carrying speciﬁc germline mutations in the APC gene. PatientsStructure of APC
gene product
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mouse models. Intestinal tumours are only observed in Apc models associated with high to
lower levels of signalling, while mammary tumours readily occur with the low signalling l
reporter assays performed on embryonic stem cells homozygous for each mutation [36–38carrying a germline mutation resulting in a truncated APC protein
retaining one 20 aa repeat are associated with the most severe form of
polyposis, whereas patients carrying mutations resulting in truncated
proteins retaining two or three 20 aa repeats are at highest risk for the
formation of desmoid tumours and polyps in the upper GI-tract, in
addition to a reduced risk for severe colorectal polyposis [65,66].
Even more dramatic differences in tumour phenotype are observed
in Apc mutant mouse models generated by us and others [67–69]
(Fig. 5). Mice with Apcmutations resulting in high β-catenin signalling
levels, such as ApcMin and ApcΔ716, mainly develop intestinal tumours
at high multiplicity (N100) with only a low penetrance of extra-
intestinal manifestations. On the other hand, age-matched animals
carrying the hypomorphic Apc1638N mutation resulting in intermedi-
ate β-catenin signalling, are characterised by a reduced incidence of
intestinal tumours (onaverage5–6)combinedwithahigh susceptibility
for several extra-intestinal tumour types such as cutaneous cysts and
desmoid tumours [70]. More recently, the Apc1572T mouse model,
characterised by a mild defect in β-catenin regulation, has been shown
to develop aggressive and metastasising mammary tumours associated
with nuclear accumulation of β-catenin [38], and a histological
appearance similar to the mammary tumours observed in transgenic
models overexpressing Wnt1 or β-catenin [71–74]. Surprisingly,
Apc1572T mice do not develop intestinal tumours, even when followed
up to old age, suggesting that the mild induction of β-catenin signalling
is not sufﬁcient to induce tumour formation in themouse intestine [38].
Further support for a dominant role of β-catenin signalling dosages in
establishing these different tumour phenotypes was provided by
Buchert et al. [50]. By combining different Apc mutant models with aβ-catenin signal
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signalling, they observed speciﬁc β-catenin signalling thresholds for
successful intestinal and liver tumour formation.
How are those phenotypic differences explained inmore detail? APC
is a tumour suppressor protein, meaning that both copies have to
acquire amutation before tumour formation ensues. All cells in the body
of FAP patients and Apc mutant mouse models carry the same
heterozygous APC/Apc germline mutation in which the remaining wild
type copy will be randomly hit by a number of somatic mutational
mechanisms including allelic loss, insertions, deletions, and single-base
substitutions. Of these, allelic loss by means of mitotic recombination
occurs at the highest spontaneous frequency, especially in the mouse
(more than 90%) [75–77]. Cells acquiring allelic loss through this
mechanismwill solely express the truncated protein originally encoded
by the germline mutation, and hence the β-catenin signalling strength
associated with that mutation (Fig. 5). In case of the Apc1572T model,
this implies that in the majority of emerging tumour cells, β-catenin
signalling is mildly activated. According to the “just-right” signalling
model this level is ideal for outgrowth of themammary tumour, but not
sufﬁcient for intestinal tumour development in the mouse. Likewise,
most nascent tumour cells in the ApcMin and ApcΔ716 models acquire
high levels ofβ-catenin signalling, ideal for the intestine but too high for
mammary cells. Further support for the strong selective pressure on
acquiring speciﬁc Apcmutations, was provided by mutation analysis of
mammary tumours developing in an Apc model associated with high
levels of signalling [78]. These tumours select for speciﬁc somatic point
mutations clustering in the codon 1521–1570 region, and are expected
to result in a low level of signalling similar to the truncated protein
expressed by the Apc1572T model.
Importantly, oncogenic CTNNB1mutations are also selected during
tumour formation. Although the S33, S37, and S45 residues are all
speciﬁed by the same TCT codon within the human CTNNB1 gene,
several tumour types show a strong preference for mutations in either
one of these residues. For example, whereas colorectal cancers mainly
show T41 and S45 mutations [10,11,23,25–27,79–81] (Fig. 6),
tumours of the endometrium, ovarium, and pilomatricomas (of hair
follicle origin) select for mutations conﬁned to residues S33 and S37
[11,24,58,59,82]. Overexpression experiments suggest that different
oncogenic CTNNB1mutations result in different levels of downstream
signalling [83], likely explaining the preference for speciﬁc mutated
residues providing the optimal growth advantage for each cell type.
In summary, not all mutations in APC or CTNNB1 result in tumour
formation. According to the “just-right” signalling hypothesis, only
thosemutations that provide sufﬁcient growth advantage for a certainFig. 6. Selection of CTNNB1mutations in colorectal tumours. Depicted is the type and location
phosphorylation residues are indicated bold. Numbers in brackets are absolute number of t
speciﬁed by the same TCT codon within the human CTNNB1 gene, colorectal tumours main
CTNNB1 mutations are selected during tumour formation.cell type, while simultaneously avoiding the induction of apoptosis,
will successfully induce tumour formation.
5. Possible alternative explanations for Apc-driven tumour
initiation
Although the concept of β-catenin signalling dosage and its impact
on tumour growth is gaining acceptance, alternative explanations for
APC-driven tumour formation have been presented. The APC gene
encodes a large multifunctional protein implicated in various other
cellular processes in addition to regulating β-catenin signalling. At its
C-terminus, APC binds to components of the microtubular skeleton.
Loss of these domains has been implicated in defects in cell migration
[84] and chromosomal segregation [85,86], both aspects of relevance
for tumorigenesis. However, the Apc1638T mouse model expressing a
truncated Apc protein retaining normal β-catenin regulation but
lacking these C-terminal domains is tumour-free, showing that loss of
these domains by itself is not sufﬁcient to induce tumour formation
and requires simultaneous activation of β-catenin signalling [36].
Nevertheless, the debate is still open to what extent loss of these
microtubular functions contributes to tumour progression.
More recently, the β-catenin dogma has been challenged by Phelps
et al. who presented data suggesting that Apc-driven tumour formation
is not initiated by nuclear accumulation of β-catenin, but instead
depends on the transcriptional corepressor C-terminal binding protein-
1 (Ctbp1) [87]. Ctbp1 physically interacts with Apc and its levels appear
to increase uponApc loss in early adenomas [87,88]. As such, changes in
Ctbp1 activity may represent a plausible alternative explanation for
tumour initiation. The main argument against a role for β-catenin put
forward by Phelps et al., was the lack of its nuclear detection in early
adenomas using immunoﬂuorescence. As discussed by Fodde and
Tomlinson, while nuclear staining for β-catenin is a reliable indicator
of Wnt activation, its absence does not exclude the robust activation
of β-catenin target genes [89]. Detection of nuclear β-catenin is more
challenging than generally appreciated. For example, nuclear β-catenin
is not detectable in frozen colorectal tumour sections [90], is not easy to
discern using immunoﬂuorescence on parafﬁn sectionswhile this is the
case using immunoperoxidase-based methods (unpublished observa-
tions), and is absent in most colorectal cancer cell lines despite strong
evidence of enhancedWnt signalling byusingmore sensitive approaches
such as β-catenin reporter assays and target gene activation. Using
immunoperoxidase-based methods, most investigators detect nuclear
accumulationofβ-catenin inearly adenomas [89,91].Moreover,whereas
oncogenic CTNNB1 mutations have been detected in a large number ofof CTNNB1mutations reported for colorectal tumours. N-terminal serine and threonine
umours reported with given mutation. Although the S33, S37, and S45 residues are all
ly acquire mutations of S45 (33/62) or T41 (21/62), strongly suggesting that speciﬁc
Table 1
Distribution of APCmutations within the proximal and distal colon. APCmutations were
grouped according to the number of 20 aa repeats present in the longest reported APC
mutation present in that tumour, as this will largely determine the residual β-catenin
regulating activity. Divisions were made according to the codon boundaries shown in
Fig. 3. Studies were only included when tumour location was properly recorded, and
when the mutation analysis minimally included the entire MCR of APC up to the ﬁrst
AXIN binding domain. Furthermore, tumours with an underlying MMR defect were
excluded. A graphical representation of these data is depicted below the table.
Differences in the number of repeats between both groups are highly signiﬁcant
(pb0.001; ordinal logistic regression model ﬁtted with SAS version 9.2, proc glimmix).
Number of 20 aa
repeats
Proximal tumours
(n=36)
Distal tumours
(n=102)
0 1 2 3 0 1 2 3
Aoki et al. [93] 0 0 1 0 0 1 0 0
Smith et al. [94] 0 6 5 1 3 29 13 2
Miyaki et al. [95] 0 2 3 1
Aust et al. [96] 0 1 2 0 0 9 0 0
Rowan et al. [47] 0 1 1 3 2 3 4 0
Scholtka et al. [97] 0 3 1 2 0 8 3 2
Ku et al. [98] 0 0 0 1 0 4 1 0
Albuquerque et al. [10] 0 0 2 0 7 9 2 0
0 13 15 8 12 63 23 4
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development of numerous tumours in the mouse intestine [92], similar
results have not yet been reported for Ctbp1.
To date, the C-terminal microtubular functions and Ctbp1 have not
been linked to the selection for speciﬁc truncatedAPCproteins retaining
between one and three 20 aa repeats that is observed in tumours.
Therefore, we believe that selection for β-catenin signalling dosage
currently represents the best explanation for the tissue-speciﬁc
selection of truncated APC proteins.++/+
APC retaining
2 or 3
20 aa repeats
Preferred β-catenin
signalling dosage 
Observed APC
mutation
Fig. 7. Selection of APC mutations and preferred β-catenin signalling strength along the c
tumours in the proximal colon are characterised by APCmutations resulting in a truncated p
levels of β-catenin signalling [10,47,93–98]. This strongly suggests that the proximal colon f
side. These mainly develop with APC truncated proteins retaining one or less frequently no o
See Table 1 for details.6. Selection for β-catenin dosage along the colorectal tract
So far, we have for simplicity considered the colorectum as one
uniform organ with an overall equal selection for a speciﬁc level of
β-catenin signalling, favouring truncated APC proteins with one or,
less frequently, two 20 aa repeats. However, regional differences in
β-catenin signalling preference affecting tumour formation also exist
along the GI-tract. Recently, we have screened a number of colorectal
tumours for mutations in Wnt-related genes with a speciﬁc focus on
colorectal location, and combined these results with a meta-analysis
of publications in which tumour location, defects in mismatch repair,
and somatic mutations were reported [10]. Focussing on APC
mutations in tumours with a functional MMR machinery, we noticed
a different mutation spectrum between both sides of the colon (see
Table 1) [10,47,93–98]. Distal colonic tumours preferentially acquire
mutations retaining one 20 aa repeat (63/102 tumours, i.e. 62%),
while long truncated APC proteins with two or three 20 aa repeats are
less common in this segment of the colon (27/102 tumours, i.e. 27%).
On the other hand, the latter mutations resulting in a moderate
signalling level are selected in tumours arising in the proximal colon
(23/36 tumours, i.e. 64%). Recently, our observation was supported by
data of Leedham et al. [99]. Analysing APC mutations in proximal and
distal polyps of FAP patients and a set of sporadic CRCs, the same
prevalence for speciﬁc APC mutations along the colorectal tract was
observed [99]. Proximal tumours also present with less nuclear
accumulation of β-catenin than their distal counterparts [100]. Overall,
these results suggest that a gradient of β-catenin signalling dosage for
tumour initiation exists along the colorectal tract with moderate levels
being preferred proximally, and higher levels towards the rectum
(Fig. 7).
This phenomenon is also observed for the location of intestinal
tumours in Apc mutant mouse models. Apc mutant mice to a large
extent develop tumours located in the small intestine, and select for
higher signalling levels associated with short truncated proteins
lacking all 20 aa domains [46,78,101]. Despite these differences
between human and mouse intestinal tumour formation, clear effects
on tumour location associated with β-catenin signalling levels have
been observed. The Apc1638N model, characterised by only a
moderate increase inβ-catenin signalling, develops intestinal tumours
almost exclusively in the duodenum and ﬁrst half of the jejunumwith
a characteristic clustering at the stomach to duodenum transition
[102–104]. A proximal preference for tumour formation has also been
reported for theApc1322Tmousemodel associatedwith a submaximal
level of β-catenin signalling [105]. In contrast, tumours developing in
the ApcMin and ApcΔ716 models, both resulting in a high dosage of
β-catenin signalling, are preferentially selected in the distal half of thepro
xim
al
dis
tal
+++/++
APC retaining 1
 or less often 0 or 2
20 aa repeats
olon. Focussing on tumours with a functional MMR machinery, we noticed that most
rotein retaining two or three 20 aa repeats associated with mild (+) to moderate (++)
or successful tumour initiation, prefers lower β-catenin signalling levels than the distal
r two repeats, resulting in a moderate (++) to high (+++) β-catenin signalling level.
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high levels of β-catenin signalling also develop some colonic tumours,
especially when expression of the mutant allele is restricted to the
distal part of the GI-tract using Cre–LoxP technology [107–109].
Interestingly, these tumours almost exclusively develop in the distal
part of the colon. Thus, both in the colon aswell as the small intestine of
themouse, theproximal region seems toprefer lower levels ofβ-catenin
signalling to initiate tumour growth than its distal counterpart.
At present, themechanismsunderlying these sidepreferences for the
optimal level of β-catenin signalling remain largely elusive. Although
β-catenin signalling in the intestine is an important determinant in
establishing cell fate, it will operate in concerted action with many
other cellular inputs. Several differences exist between the proximal
and distal colon that may cooperate with the defect in β-catenin
signalling to successfully initiate tumour growth [7]. For example,
short-chain fatty acids such as butyrate, are produced at considerably
higher levels by bacterial fermentation reactions in the proximal
colon [110]. In vitro, these fatty acids have been shown to induce an
apoptotic response when administered to colorectal cancer cell lines
[111], suggesting that the higher fatty acid levels present in the
proximal colon reduces the apoptotic threshold, which in turn may
lead to a preference for a moderate activation of β-catenin signalling
to initiate tumour growth. A similar line of reasoning can be postulated
for bile acids of which various structural variants also differ in their
concentrations along the colon [112,113]. Moreover, both sides of the
colon differ signiﬁcantly in their gene expression proﬁles [114]. For
example, CDX2 is expressed at higher levels in the proximal colon [115].
Interestingly, Aoki et al. have shown that a 50% reduction in Cdx2 levels
results in a strong shift frommainly small intestinal tumours towards a
large intestinal tumour phenotype in ApcΔ716mice [106].With respect
to β-catenin signalling, Leedham et al. presented data suggesting that
the proximal small intestine as well as the proximal colon presentTable 2
MMR deﬁcient tumours acquire signiﬁcantly more often truncated APC proteins
retaining two or three repeats than their MMR proﬁcient counterparts, which mainly
develop with truncated proteins retaining one such repeat. Tumours were only
included if the MMR status was clear. Tumours were included irrespective of location.
Differences in number of repeats between both groups are highly signiﬁcant
(pb0.0001; ordinal logistic regression model ﬁtted with SAS version 9.2, proc glimmix).
Number of 20 aa
repeats
Functional mismatch
repair (n=345)
Defective mismatch
repair (n=63)
0 1 2 3 0 1 2 3
Huang et al. [22] 13 24 13 5 6 4 14 2
Konishi et al. [122] 0 1 2 1
Olschwang et al. [116] 21 25 8 4 0 0 1 0
Rowan et al. [47] 2 9 7 4 0 1 3 2
Lovig et al. [20] 14 62 17 7 1 0 2 4
Smith et al. [94] 3 35 18 3
Miyaki et al. [95] 0 2 3 1
Domingo et al. [123] 0 1 5 3
Scholtka et al. [97] 0 11 4 4 0 0 0 1
Ku et al. [98] 0 4 1 1 0 0 0 3
Albuquerque et al. [10] 7 9 4 0 0 0 6 0
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1 2 30with higher basal levels of β-catenin signalling [99]. Based on this
observation, they postulated that this might explain the selection for
mutations leading to a mild increase in β-catenin signalling on the
proximal side, as a lower increase in signalling is required to reach a
hypothetical threshold for tumour initiation.
7. Colorectal cancers choosing sides: tumours having a functional
MMR system
Asmentioned previously, tumours characterised by a deﬁcientMMR
system are more frequently observed at the proximal side of the colon,
whereasmost others occur at the distal side.We propose that these side
preferences may in part be explained by the speciﬁc acquired genetic
defects in β-catenin signalling along the colorectal tract. As outlined
below, MMR deﬁcient tumours more frequently acquire mutations in
APC or CTNNB1 that are ideal for the proximal colon, whereas the ones
with a functional MMR more often acquire APC mutations optimal for
the distal colon. As depicted in Table 2 (left section), mutations leading
to truncated APC proteins retaining one 20 aa repeat are the most
commonly observed mutations in tumours with a functional MMR
system (181/345, i.e. 53%) [10,20,22,47,94,95,97,98,116]. In part, the
high frequency of these mutations is likely to be explained by the fact
that the region between the ﬁrst and second repeat contains an
(AAAAG)2direct repeat around codon1309 that is prone to a deletion of
5 bps, representing one of the most common somatic APC mutations
[117]. Secondly, the APC sequence between the ﬁrst and second repeat
codes for 146 amino acid residues, which is approximately twice the
number of codons between repeats two and three and between repeat
three and the ﬁrst AXIN binding motif, 82 and 65 codons respectively
(Fig. 3). Thus, based on sequence length, the region in between the ﬁrst
and second repeat is expected to acquire half of themutations occurring
within the mutation cluster region. Overall, in colorectal cells with a
functional MMR system this leads to the generation of tumour cells
preferentially expressing truncatedAPCproteinswith one repeat,which
provides the ideal β-catenin signalling level for the distal colon.
According to the “just-right” signalling hypothesis, the same type of
mutation is believed to induce an apoptotic response resulting from the
high level of β-catenin signalling when occurring in the proximal colon,
thereby preventing tumour initiation in this part of the colon. Therefore,
we propose that the higher chance of obtaining a mutation leading to a
truncated APC protein retaining one 20 aa repeat, shifts the balance of
tumours towards the distal colon.
8. Colorectal cancers choosing sides: mismatch repair deﬁcient
tumours
In MMR deﬁcient intestinal cells the predominant mutational
mechanism consists of mutations at the nucleotide level. Overall, a
defective MMR system leads to a 10–30 fold higher induction of single
basepair substitutions [118–120]. However, sequences most prone to
mutations are the ones containing stretches of mono- or dinucleotide
repeats, of which the mutation frequency can be increased up to 100-
fold, depending on the length of the repeat. As such, genes containing
these repetitive sequences in their reading frame will be most prone
to mutation in a MMR deﬁcient background [5,6,121]. The APC gene
contains several of these repetitive sequence features, which are
indeedmore frequentlymutated inMMR deﬁcient tumours [20,22]. In
Fig. 8 we have highlighted in red the sequences prone tomutation in a
MMR deﬁcient background within the region harbouring the ﬁrst
three 20 aa repeats. As depicted in Table 3, mutations in these
repetitive sequences, i.e. codons 1455 (A5), 1462 (AG5) or 1554 (A6),
are observed in about 37% (23/63) of MMR deﬁcient colorectal
tumours carrying APC mutations, whereas these mutations are
observed in less than 5% (16/345) of tumours with a functional
MMR system [10,20,22,47,95,97,98,116,122,123]. Mutations at one of
these hotspots lead to the generation of a truncated APC protein
Fig. 8. Expected hotspots for mutation within APC in MMR deﬁcient tumours. The APC gene contains several mono- and dinucleotide stretches that are prone to mutation in a MMR
deﬁcient background. Here, we have highlighted in red the mononucleotide stretches of 5 or more of the same kind as well as the dinucleotide repeats with at least 4 repeats, in the
region between the ﬁrst 20 aa repeat and the ﬁrst AXIN binding domain. Mutations at one of these hotspots lead to the generation of a truncated APC protein retaining two or three
20 aa repeats. Colour codes for structural domains are as in Fig. 3. The (AAAAG)2 direct repeat around codon 1309, often mutated in MMR proﬁcient CRCs, is underlined.
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mutations at one of these hotspots superimposed on the normal
mutation spectrum, likely explains the high proportion of MMR
deﬁcient tumours (49/63 tumours, i.e. 78%) that obtain truncated APC
proteins retaining two or three repeats (see Table 2), which is
considerably higher than observed in tumours with a functional MMR
system (104/345 tumours, i.e. 30%).
In about 50% of MMR deﬁcient tumours APC mutations are
observed [10,20,22–26]. An additional 10% obtain oncogenic CTNNB1
mutations, resulting in amoderate signalling activity equivalent to the
truncated APC proteins with 2–3 repeats. As such, these mutations are
expected to be selected in the proximal colon, which is in accordance
with over 80% (47/58) of tumours carrying CTNNB1 mutations being
detected on this side [10,25–27,80,81]. Recently, we have obtained
additional evidence for this observation by screening 54 MMR
deﬁcient tumours for CTNNB1 mutations. We conﬁrmed that these
mutations occur more frequently in proximal tumours (15/36, i.e.
42%) than in their distal counterparts (1/18, i.e. 6%), irrespective of
sporadic or familial origin (pb0.01, Chi-square test, unpublished
observations).
In summary, due to the underlying mutational mechanism under
MMRdeﬁcient conditions, a signiﬁcantproportion of cells acquire eitherinactivating mutations in the APC gene following the second and third
repeat, or oncogenic CTNNB1 mutations. Both types of mutations are
associated with a low to moderate activation of β-catenin signalling.
According to the “just-right” signalling model, this provides the ideal
level for successful tumour initiation in the proximal colon, whereas it
will not supply sufﬁcient growth advantage in the distal colon. As a
result, MMR deﬁcient cells are more successful in forming a detectable
tumour on the proximal side.
9. Concluding remarks
We propose that the side preference of colorectal tumours may in
part be explained by their particular mutational mechanism, resulting
in APC and CTNNB1 mutations leading to a speciﬁc level of β-catenin
signalling that is ideal for either side of the colon. Obviously, our
hypothesis only applies to colorectal tumours initiated by enhanced
β-catenin signalling, which is the case for the great majority of
tumours with a functional MMR system. However, among the MMR
deﬁcient tumours, a mutation in CTNNB1 or APC has not been
reported in about 40% of the tumours. There are several potential
explanations for this apparent lower involvement of the β-catenin
signalling pathway in MMR deﬁcient tumours. The ﬁrst one is of a
Table 3
The potential mutational hotspots, i.e. codons 1455, 1462, and 1554, marked in Fig. 8,
are mutated in about 37% (23/63) of MMR deﬁcient colorectal tumours carrying APC
mutations, whereas this is only the case in less than 5% (16/345) of tumours with a
functional MMR system. These differences are highly signiﬁcant (Fisher exact test;
*pb0.01; **pb0.001).
Codons Functional mismatch
repair (n=345)
Defective mismatch
repair (n=63)
1455 1462 1554 1455 1462 1554
Huang et al. [22] 0 1 1 2 1 2
Konishi et al. [122] 0 1 1
Olschwang et al. [116] 0 0 1 0 0 0
Rowan et al. [47] 0 0 4 0 0 1
Lovig et al. [20] 0 0 6 0 1 3
Miyaki et al. [95] 0 0 0
Domingo et al. [123] 2 2 2
Scholtka et al. [97] 0 1 1 0 0 1
Ku et al. [98] 0 0 1 0 0 3
Albuquerque et al. [10] 0 0 0 1 0 0
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high level of lymphocytic inﬁltration [5,6]. Since none of the quoted
investigations have enriched their samples for tumour cell content,
e.g. by laser capture microdissection, mutations may have been
obscured by the DNA isolated from the large numbers of contami-
nating normal cells. Secondly, in 30–40% ofMMR tumours amutation
or inactivation of either AXIN1 or AXIN2 is identiﬁed, some of which
appear to be the sole defect in theWnt/β-catenin signalling pathway
in these tumours [10,27–30]. Given the redundant nature of both
Axin homologues [124], a modest increase in β-catenin signalling is
to be expected, which is in line with a proximal preference for MMR
deﬁcient tumours. Lastly, a subset of colorectal tumours arises
without an underlying defect in the Wnt/β-catenin signalling
pathway. In support of this, the proximal colon shows more tumours
with no apparent nuclear accumulation of β-catenin [100], although
β-catenin IHC should be interpreted with caution. Alternative
explanations have to be provided to explain the side preferences of
these tumours. Most MMR deﬁcient tumours carry mutations in the
TGFBR2 gene leading to resistance to the anti-proliferative effects of
TGF-β [121,125]. The proximal colon might be more sensitive to loss
of this inhibitory effect for thus far unknown reasons, resulting in the
outgrowth of more MMR deﬁcient tumours on this side. Also,
activating BRAF mutations have strongly been correlated with
proximal sporadic MMR deﬁcient tumours [123,126,127]. BRAF is a
member of the RAF family of kinases acting upstream of MEK1/2
kinases in response to RAS signals. As such, BRAF mutations are
considered as an alternative to KRAS2mutations to activate the same
downstream MEK–MAPK signalling pathways [128]. In line with the
“just-right” signalling hypothesis, it may be postulated that activat-
ing BRAF mutations provide the optimal level of downstream
signalling ideal for the proximal colon, and therefore support tumour
growth on this side. However, experimental support for this
hypothesis is currently lacking.In ourmanuscript, we have highlighted the importance of β-catenin
signalling dosages for the tumorigenic process, and presented data
supporting our hypothesis that selection for speciﬁc dosages along the
colorectal tract may in part explain the side preferences of colorectal
tumours. It shows that we should not perceive mutations in signalling
pathways merely as on/off switches, but that we should appreciate the
nuances of signalling. The dosage-dependence as described here for
β-catenin signalling will also be of relevance for other signalling
pathways commonly involved in cancer development.Acknowledgements
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Final note
Following acceptance of our manuscript, the DDW 2011 confer-
ence abstract of Leedham et al. quoted here as reference no. 99, has
been submitted as a full paper (personal communication). In this paper
they describe the existence of a physiological Wnt signalling gradient
along the intestinal tract. Based on this observation, they indepen-
dently propose a mechanism for the side preferences of colorectal
tumours, similar to ours.References
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